
Drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.
Cox Enterprises formed part of a consortium that provided $126m for Iora Health, a healthcare provider whose investors also include Humana and General Electric.
Illumina Ventures returned to reinvest in a $21.8m round for the DNA-analysis system developer having led its series A round in 2018.
Sonoma Biotherapeutics has emerged from stealth with $40m from investors including Lyell Immunopharma and is developing regulatory T-cell therapies for autoimmune and degenerative diseases.
Biocodex returned for a $19.8m round that boosted microbiome drug developer MaaT Pharma's overall funding to more than $33m.
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
The GV and Wuxi AppTec-backed drug development software producer floated above its range and saw its shares rise 68% on their first day of trading.
The tissue analysis technology developer has now raised more than $37m, having received $23.6m in a first tranche of its series C round that was led by PHC Holdings.
The personalised therapy management platform closed a round led by Cardinal Health with backing from Novartis and Kite Pharma, taking its overall funding to more than $82m.
Alphabet, Editas and Bio Palette-backed genomic medicine developer Beam will raise $180m in an upsized initial public offering three years after being spun out of Harvard University.